Podcast: Download (Duration: 36:44 — 50.6MB)
From coyotes to biohacking entrepreneurs, it seems everyone is experimenting with the effects of psilocybin these days.
Psilocybin is the naturally occurring psychedelic compound found in mushrooms. The mind-altering effects of ‘shrooms first gained counterculture notoriety during the 60s among recreational users. However, a quiet, scientifically backed renaissance has begun that is adding legitimacy to the use of hallucinogens for reasons that extend beyond recreational relaxation.
In the United States, psilocybin is a Schedule I substance under the Controlled Substances Act, which means the compound has a high potential for abuse, no currently accepted medical use, and a lack of accepted safety for use under medical supervision. Consequently, the mystical experiences provided by psilocybin have heretofore been sought out by those on the outer edges of the law.
James Fadiman has been among the most prevalent of proponents, advocating the benefits of microdosing to achieve enhanced focus, mood and creativity for sustained periods of time.
Tim Ferriss of The 4 Hour Work Week, recently picked up the advocacy torch to lead the way toward legitimizing the therapeutic and medical use of psilocybin. His personal and financial support have brought media attention to topic.
So What Makes Psilocybin So Special?
What has piqued the interest of both the medical research community and entrepreneurial luminaries, bringing these magical mushrooms out of the thicket and into the open?For the last decade, members of the scientific and medical community have been quietly investigating the use of this psychedelic as a viable, sustaining and greatly needed treatment for debilitating physical and psychological maladies such as depression and addiction.
For the last decade, members of the scientific and medical community have been quietly investigating the use of this psychedelic as a viable, sustaining and greatly needed treatment for debilitating physical and psychological maladies such as depression and addiction. This week Jesse speaks with Dr. Frederick Barrett, a researcher on a team led by Dr. Roland Griffiths at John Hopkins University School of Medicine. The team is conducting a potentially ground-breaking pilot study on psilocybin focused on addressing treatment-resistant depression.
As Dr. Barrett shares with Jesse, the benefits of psilocybin, if administered properly could potentially be a personal and public health game changer. Yes, there are risks and contraindications and not everyone has a positive experience, but the therapeutic benefit that has been demonstrated in the research to date is compelling. While the studies are small, many participants report profound mystical experiences that rank as being in their top five or ten lifetime experiences — right up there with the birth of a child!
Findings also indicate that psilocybin is an effective treatment for depression, providing long-term, positive effects on mood, emotional functioning and well-being. Even more notable is that limited treatment of psilocybin is needed to achieve these long-lasting benefits, far better outcomes than often reported with the typical pharmacological depression treatments.
Listen in to learn all the details. Like, What exactly is a mystical experience and how common are they? How much psilocybin are we talking about? Will there ever be a psychedelic treatment model to treat depression? And will pharmaceutical companies be likely to invest in psilocybin?
It’s fascinating stuff and might lead the ever-hopeful to expect that with time, funding and research, psychedelics — and psilocybin in particular — might just accompany the vast array of SSRIs on the pharmacy shelves.
A note for our UK-based listeners: Please sign & share this petition to try and help secure the future of nootropics in the UK. (The petition can only be signed by those in the UK, or with UK Citizenship.)
Links you’ll want to click…